Advancing transformative medicines for people living with psychiatric and neurological conditions
Advancing transformative medicines for people living with psychiatric and neurological conditions
Pioneering the development of cognitive treatments through game-changing technologies
Pioneering a new category of oral therapies based on defined bacterial consortia
Engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers
A voice-based artificial intelligence platform to detect changes in health
Engineering hydrogels to enable the oral administration of peptide therapeutics (e.g., GLP-1 agonists)
Note: This figure represents the stage of development for each Founded Entity’s most advanced therapeutic candidate.PureTech retains control of Entrega, Inc., and it is consolidated in PureTech’s financial statements. PureTech maintains ownership of equity interests, but does not control, Karuna Therapeutics, Inc., Akili, Inc., Sonde Health, Inc. Vor Biopharma Inc., and Vedanta Biosciences, Inc. Relevant ownership interests for non-public Founded Entities, Vedanta, Sonde and Entrega were calculated on a partially diluted basis (as opposed to a voting basis) as of June 30, 2023, including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Karuna, Akili and Vor ownerships were calculated on a beneficial ownership basis in accordance with SEC rules as of October 31, 2023, August 3, 2023 and August 4, 2023, respectively. As of March 1, 2023, the date on which PureTech was deemed to no longer control Vedanta Biosciences, PureTech’s percentage ownership of Vedanta Biosciences was approximately 40.8%. Vedanta’s 2023 $106.5 million financing round was structured as convertible debt. PureTech’s current ownership does not take into account any potential future dilution, if applicable, as a result of conversion of that debt amount. With the exception of Plenity® and EndeavorRx®, candidates are investigational and have not been cleared by the FDA for use in the U.S.
2 Funding figure can include private equity financings, loans and promissory notes, public offerings or grant awards, and gross proceeds from SPAC mergers. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations.
3 As of March 22, 2023, PureTech has sold its right to receive a 3% royalty from Karuna to Royalty Pharma on net sales up to $2 billion annually, after which threshold PureTech will receive 67% of the royalty payments and Royalty Pharma will receive 33%. PureTech retains its equity ownership in Karuna. Additionally, under its license agreement with Karuna, PureTech retains the right to receive milestone payments upon the achievement of certain regulatory approvals and 20% of sublicense income.